Explosion of Data Come From Innovative Combos in CLL The progress made with novel combination regimens is unprecedented

[lankisterguy]

Video recaps of significant papers presented at 25th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

view.email.onclive.com/?qs=...

CONFERENCE COVERAGE | NEWS NETWORK | ONCLIVE TV | PEER EXCHANGE | INSIGHTS | EVENTS

Chronic Lymphocytic Leukemia

Explosion of Data Come From Innovative Combos in CLL onclive.com/view/explosion-...

The progress made with novel combination regimens combined with their game-changing data in both frontline and relapsed/refractory chronic lymphocytic leukemia is unprecedented.

Ianalumab/Ibrutinib Combo Shows Promising Activity in CLL click.email.onclive.com/?qs...

The combination of ianalumab and ibrutinib demonstrated encouraging clinical activity in patients with chronic lymphocytic leukemia currently receiving ibrutinib therapy.

Time-Limited Therapy Takes Center Stage in Frontline and Relapsed/Refractory CLL click.email.onclive.com/?qs...

Fixed-duration treatment that leads to deep treatment-free remissions has become the prioritized strategy for patients with chronic lymphocytic leukemia.

Final GENUINE Data Support Addition of Ublituximab to BTK Inhibitors in Relapsed/Refractory, High-Risk CLL click.email.onclive.com/?qs...

The addition of ublituximab to ibrutinib led to a statistically higher overall response rate over ibrutinib alone in patients with relapsed/refractory, high-risk, chronic lymphocytic leukemia.

[Sushibruno]

Wow very encouraging 🙂. Thank you.

[AussieNeil Partner Administrator]

Snap! but such great news is well worth repeating healthunlocked.com/cllsuppo...